These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 30635053)

  • 1. Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients.
    Zhao B; Zhao H; Zhao J
    J Immunother Cancer; 2019 Jan; 7(1):9. PubMed ID: 30635053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction to: The effect of Neuroligin-2 absence on sleep architecture and electroencephalographic activity in mice.
    Seok BS; Cao F; Bélanger-Nelson E; Provost C; Gibbs S; Jia Z; Mongrain V
    Mol Brain; 2019 Jan; 12(1):9. PubMed ID: 30700334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.
    Johnson DH; Zobniw CM; Trinh VA; Ma J; Bassett RL; Abdel-Wahab N; Anderson J; Davis JE; Joseph J; Uemura M; Noman A; Abu-Sbeih H; Yee C; Amaria R; Patel S; Tawbi H; Glitza IC; Davies MA; Wong MK; Woodman S; Hwu WJ; Hwu P; Wang Y; Diab A
    J Immunother Cancer; 2019 Apr; 7(1):107. PubMed ID: 30995944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.
    Cates CJ; Lasserson TJ; Jaeschke R
    Cochrane Database Syst Rev; 2009 Jul; (3):CD006922. PubMed ID: 19588410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction to: MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus.
    Slotta-Huspenina J; Drecoll E; Feith M; Habermehl D; Combs SE; Weichert W; Bettstetter M; Becker K; Langer R
    J Transl Med; 2018 May; 16(1):128. PubMed ID: 29769068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction to: Seroprevalence and determinants of transfusion transmissible infections among voluntary blood donors in Homabay, Kisumu and Siaya counties in western Kenya.
    Onyango CG; Ogonda L; Guyah B; Okoth P; Shiluli C; Humwa F; Opollo V
    BMC Res Notes; 2018 Jun; 11(1):410. PubMed ID: 29945668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of human albumin--serious adverse events reported worldwide in 1998-2000.
    Vincent JL; Wilkes MM; Navickis RJ
    Br J Anaesth; 2003 Nov; 91(5):625-30. PubMed ID: 14570782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
    Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
    Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
    Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
    J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events.
    Cates CJ; Lasserson TJ; Jaeschke R
    Cochrane Database Syst Rev; 2009 Apr; (2):CD006924. PubMed ID: 19370661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regular treatment with formoterol for chronic asthma: serious adverse events.
    Cates CJ; Cates MJ; Lasserson TJ
    Cochrane Database Syst Rev; 2008 Oct; (4):CD006923. PubMed ID: 18843738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction to: Recurrent pregnancy loss is associated to leaky gut: a novel pathogenic model of endometrium inflammation?
    Tersigni C; D'Ippolito S; Di Nicuolo F; Marana R; Valenza V; Masciullo V; Scaldaferri F; Malatacca F; de Waure C; Gasbarrini A; Scambia G; Di Simone N
    J Transl Med; 2019 Mar; 17(1):83. PubMed ID: 30876477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
    Hellmann MD; Rizvi NA; Goldman JW; Gettinger SN; Borghaei H; Brahmer JR; Ready NE; Gerber DE; Chow LQ; Juergens RA; Shepherd FA; Laurie SA; Geese WJ; Agrawal S; Young TC; Li X; Antonia SJ
    Lancet Oncol; 2017 Jan; 18(1):31-41. PubMed ID: 27932067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction to: Screening and computational analysis of colorectal associated non-synonymous polymorphism in CTNNB1 gene in Pakistani population.
    Razak S; Bibi N; Dar JA; Afsar T; Almajwal A; Parveen Z; Jahan S
    BMC Med Genet; 2020 Feb; 21(1):39. PubMed ID: 32093642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction to: Pericardial effusion under nivolumab: case-reports and review of the literature.
    Saade A; Mansuet-Lupo A; Arrondeau J; Thibault C; Mirabel M; Goldwasser F; Oudard S; Weiss L
    J Immunother Cancer; 2019 Dec; 7(1):335. PubMed ID: 31791420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.
    Kudo T; Hamamoto Y; Kato K; Ura T; Kojima T; Tsushima T; Hironaka S; Hara H; Satoh T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Doki Y; Kitagawa Y
    Lancet Oncol; 2017 May; 18(5):631-639. PubMed ID: 28314688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
    Alnabulsi R; Hussain A; DeAngelis D
    Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
    Aggarwal P
    Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
    [No Abstract]   [Full Text] [Related]  

  • 20. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.